Pharmacological research progress of Ranaconitine: from traditional herbs to modern analgesic candidate molecules
Introduction/Overview
Natural products have always been an important source of innovative drug discovery, among which diterpenoid alkaloids have attracted much attention due to their complex and diverse structures and significant biological activities. Ranaconitine (CAS number: 1360-76-5) is a C19 diterpenoid alkaloid isolated from plants of the Aconitum genus. It is one of the important active ingredients in traditional Chinese medicines such as Aconitum and Aconitum, in addition to the main toxic components such as aconitine, aconitine, and aconitine. Traditionally, Aconitum drugs have been used in traditional Chinese medicine clinical practice to treat conditions such as rheumatism, abdominal pain, and traumatic injuries. However, their strong toxicity and narrow treatment window limit their widespread application. In recent years, with the advancement of separation and purification technology and the deepening of pharmacological research, aconitine has gradually emerged from numerous aconitine alkaloids due to its relatively low acute toxicity and clear analgesic activity, becoming a research hotspot. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, pharmacological evaluation, and clinical application prospects of aconitine, in order to provide comprehensive scientific references for the in-depth research and potential drug development of this compound.
Chemical structure and physicochemical properties
The molecular formula of Ranaconitine is C32H44N2O8, with a molecular weight of 600.7090 Da. Its structure belongs to the typical C19 diterpenoid alkaloid (aconitine type), and its skeleton is composed of a six ring system, including a tetracyclic diterpenoid nucleus and a nitrogen-containing six membered ring (piperidine ring). Compared with highly toxic aconitine, Ranaconitine usually connects different ester side chains at the C8 position, which is considered one of the key factors for its relatively low toxicity.
From the perspective of pharmacological parameters, the lipid water partition coefficient (LogP) of aconitine is 1.9875, indicating its moderate lipophilicity and favorable transmembrane absorption. Its topological polar surface area (TPSA) is 147.0200 Å ², which is a relatively high value, indicating the presence of numerous hydrogen bond acceptors and donors (such as multiple methoxy and hydroxyl groups) in the molecule, which may affect its membrane permeability. The water solubility data is 0.0864 (usually measured in mg/mL or logS), indicating that it is a slightly soluble or poorly soluble compound in water, which may be a potential limiting factor for its oral bioavailability. These physicochemical properties provide key information for the development of their formulations, such as the need for solubilization technology.
Plant sources and extraction methods
Ranaconitine mainly comes from various plants in the Aconitum genus of the Ranunculaceae family, such as monkshood、monkshood、Huanghua Aconitum Wait. There are significant differences in its content among different species and parts (such as main roots and lateral roots). Usually, this alkaloid has a low content in plants and often coexists with a series of structurally similar diterpenoid alkaloids, which poses challenges for its isolation and purification.
The traditional extraction method mainly uses solvent extraction. The common process is to extract or reflux the dried root powder of Aconitum plants with alcohols (such as ethanol, methanol) or dilute acid aqueous solution, and concentrate it to obtain the total alkaloid extract. Subsequently, the acid soluble and alkaline precipitation characteristics of alkaloids were utilized for preliminary purification: the extract was dissolved in dilute acidic water, filtered and alkalized to allow the alkaloids to precipitate freely, and then extracted with organic solvents such as chloroform and ether.
Modern separation and purification techniques have greatly improved the efficiency and purity of obtaining aconitine.High-speed countercurrent chromatography HSCCC has become an effective tool for separating aconite alkaloids with similar structures due to its advantages such as no need for solid carriers, high recovery rate, and resistance to irreversible adsorption. By optimizing the two-phase solvent system (such as n-hexane ethyl acetate methanol water system), efficient separation of aconitine from aconitine, aconitine, etc. can be achieved. In addition,Preparation type high-performance liquid chromatography Prep HPLC is the final key step in obtaining high-purity monomer compounds, often using a reverse phase C18 chromatography column with acetonitrile water or methanol water (buffer salts such as triethylamine phosphate are often added to improve peak shape) as the mobile phase for gradient elution. Combine mass spectrometry(MS) and Nuclear Magnetic Resonance NMR can be used for online or offline detection to accurately identify and collect target components.
Pharmacological activity research
Numerous preclinical studies have shown that aconitine has a wide range of pharmacological activities, with the most prominent and profound being its Analgesic effect。
-
Analgesic activity Multiple animal models (such as mouse hot plate method, tail flick method, rat formalin test, acetic acid writhing test, chronic neuropathic pain model) have confirmed that aconitine can produce dose-dependent analgesic effects after intraperitoneal injection or oral administration. Its analgesic intensity can be comparable to some classic nonsteroidal anti-inflammatory drugs or weak opioid drugs within a certain dosage range. It is worth noting that in some studies, its analgesic effect was not accompanied by significant motor coordination disorders or sedative effects, suggesting that it may have good therapeutic selectivity.
-
anti-inflammatory activity Inflammation and pain are often mutually causal. Research has shown that aconitine exhibits anti-inflammatory effects in inflammation models such as carrageenan induced foot swelling and cotton ball granuloma in rats, and can inhibit swelling and inflammatory exudation. This provides a synergistic mechanism for its analgesic effect.
-
Other activities There are also a few studies reporting that aconitine may have local anesthetic and antiarrhythmic activities, but the strength and specificity of these effects need further verification, and its relationship with the main analgesic effect is not yet clear.
safety evaluation Compared with highly toxic components such as aconitine, the acute toxicity (such as LD50) of aconitine is significantly reduced. However, as a member of the aconite alkaloid family, its potential toxicity to the heart (sodium ion channels) and nervous system still requires high vigilance. Long term toxicity, cumulative toxicity, and special toxicology studies (such as reproductive toxicity) currently have insufficient data, which is a gap that must be filled in future clinical translation.
Mechanism of action and molecular targets
The analgesic mechanism of Ranaconitine is complex, involving multi-target regulation, which corresponds to its complex chemical structure. According to existing research, its targets can be classified into the following categories:
-
Ion channel target：
- TRPV1 and TRPA1 Transient receptor potential vanillic acid subtype 1 (TRPV1) and anchored protein subtype 1 (TRPA1) are important pain receptors activated by capsaicin, thermal stimulation and mustard oil, cold stimulation and inflammatory mediators, respectively. Research suggests that aconitine may be involved in these channels modulator It may alleviate inflammatory pain and neuropathic pain by inhibiting its excessive activation.
- Voltage gated sodium channels (VGSCs)Aconitum alkaloids are commonly considered as agonists of VGSCs, causing sustained channel opening and triggering neurotoxicity and cardiac toxicity. The mode of action of aconitine on this channel may be different, and it is hypothesized that it may exhibit certain effects at low concentrations Use dependency blockade This may be one of the reasons for its analgesic effect and low toxicity, as it inhibits the abnormal discharge of pain neurons, but direct electrophysiological evidence is needed to confirm its effectiveness.
-
G protein coupled receptors (GPCRs) targets：
- Opioid receptor system Molecular docking and partial pharmacological antagonism experiments suggest that aconitine may have certain affinity or regulatory effects on the μ - opioid receptor (OPRM1), δ - opioid receptor (OPRD1), and κ - opioid receptor (OPRK1), which may mediate the central analgesic component. However, further research is needed to determine whether it is a typical opioid receptor agonist and whether it can cause common tolerance and addiction to opioid drugs.
- Cannabinoid receptor 1 (CNR1)The endocannabinoid system is involved in pain modulation. Ranaconitine may indirectly affect downstream signaling pathways by acting on CNR1, producing analgesic and anti-inflammatory effects.
- Dopamine D2 receptor (DRD2)The dopaminergic system is involved in regulating the emotional dimension of pain perception. The interaction between Ranaconitine and DRD2 may be related to its regulation of pain emotion components.
-
Enzyme and transporter targets：
- Cyclooxygenase (PTGS1/COX-1, PTGS2/COX-2)Ranaconitine may exert anti-inflammatory and analgesic effects by inhibiting the activity of COX-1 and COX-2, reducing the synthesis of pain and inflammatory mediators such as prostaglandins, similar to the mechanism of action of nonsteroidal anti-inflammatory drugs.
- 5-hydroxytryptamine transporter (SLC6A4/SERT)5-hydroxytryptamine is an important downregulating inhibitory pain modulating neurotransmitter. Regulating SERT function can affect the concentration of 5-HT in synaptic cleft. Ranaconitine may enhance the analgesic effect of the 5-HT system by affecting SERT.
In summary, the analgesic mechanism of aconitine is not through a single "magic bullet" target, but presents a Multi target, networked regulation The characteristics. It may simultaneously act on multiple pain signal generation, transmission, and modulation pathways in both the peripheral and central nervous systems. This characteristic may give it potential advantages for complex chronic pain (such as neuropathic pain and inflammatory pain), but it also poses challenges for fully elucidating its mechanism of action.
Evaluation of drug properties and pharmacokinetics
Based on the provided pharmacological parameters and existing research, the preliminary evaluation of the pharmacological properties of aconitine is as follows:
- Absorption and distribution Moderate LogP values are beneficial for its passive diffusion absorption, but higher TPSA and lower water solubility may limit its oral absorption rate and degree.Prediction of blood-brain barrier (BBB) permeability as' low 'This is a crucial piece of information. This means that aconitine may have difficulty entering the central nervous system in large quantities, and its analgesic effect may depend more on targets at the peripheral and spinal cord levels (such as peripheral TRP channels, spinal opioid receptors, etc.). This may to some extent reduce the risk of central neurotoxicity, but it may also weaken its effectiveness in acting through potent central targets such as opioid receptors in the brain.
- Metabolism and excretion As a complex alkaloid containing multiple methoxy groups and ester bonds, aconitine is likely to undergo extensive metabolism in the body, with the main metabolic organ being the liver. The CYP450 enzyme system (such as CYP3A4) may be involved in its oxidative metabolism, and esterases may hydrolyze its side chain ester bonds. The activity and toxicity of its metabolites are currently poorly understood. Prototype drugs and metabolites may be excreted through the kidneys or bile.
- Security Warning：
- HERG inhibition Predicted as' no ', this is a positive signal indicating a relatively low risk of causing QT interval prolongation and apical torsion ventricular tachycardia in the heart, but experimental verification is needed.
- Genotoxicity The Ames test predicted a value of 0.0, indicating that it may not be mutagenic in this testing system, but final confirmation from in vitro and in vivo experiments is still required.
- Current status of pharmacokinetic research At present, there is still a lack of pharmacokinetic studies on the Ranaconitine system, such as absolute bioavailability, tissue distribution, plasma protein binding rate, major metabolic pathways, etc. Establishing sensitive and specific in vivo analytical methods (such as LC-MS/MS) and conducting comprehensive ADME research are the necessary steps to promote their clinical application.
Clinical application prospects and prospects
The research and development prospects of Ranaconitine present both opportunities and challenges.
Potential advantages and directions：
1. New multi-target analgesic drugs For complex chronic pain, single target drugs often have insufficient efficacy. The multi-target properties of aconitine may provide a new therapeutic strategy, especially for pain types that do not respond well to traditional NSAIDs or opioid drugs.
2. Peripheral restrictive analgesics Its low BBB permeability can be converted into an advantage by developing analgesics that primarily act on the periphery, with the aim of minimizing central side effects such as sedation, respiratory depression, and addiction.
3. Structural optimization and derivative development Using it as the mother nucleus for structural modification, with the aim of Enhance analgesic efficacy, reduce potential toxicity, and improve pharmacokinetic properties(such as improving water solubility and optimizing metabolic stability). For example, modifying the ester side chains at C8 and C14 positions may result in novel derivatives that separate activity and toxicity.
4. combination therapy As an adjuvant analgesic, when used in combination with existing drugs such as low-dose opioid drugs and gabapentin, it may produce a synergistic effect, reducing their respective dosages and side effects.
Main challenges faced：
1. Accurate definition of treatment window Although the toxicity is lower than that of aconitine, the window between its effective dose and toxic dose still needs to be strictly determined in higher-level animal models and ultimately in humans.
2. Mechanism complexity Multi targeting is both an advantage and a 'black box'. It is necessary to clarify which are the key targets that exert therapeutic effects and which are off target effects that cause adverse reactions, which requires the use of various technical methods such as chemical biology, gene knockout animals, and highly selective probes.
3. Pharmacokinetic bottleneck Low solubility and potential first pass effects are major challenges for its oral administration. It is necessary to develop suitable drug delivery systems, such as nanocrystals, liposomes, cyclodextrin inclusion complexes, etc., to improve their bioavailability.
4. Regulatory and cognitive barriers Due to the background of "toxic traditional Chinese medicine", it may face additional cautious evaluation in regulatory approval and clinical acceptance. It is necessary to provide far beyond conventional and solid security data.
Conclusion
Ranaconitine, as a natural diterpenoid alkaloid derived from traditional medicinal plants, has become a valuable lead compound for the development of new analgesic drugs due to its clear analgesic activity and relatively low acute toxicity. Modern pharmacological research has preliminarily revealed a complex network of analgesic and anti-inflammatory effects through acting on multiple targets such as TRPV1/TRPA1, opioid receptors, COX, etc. However, its low BBB permeability, potential metabolic stability issues, and unclear toxicity risks constitute the main obstacles to its drug conversion. Future research should focus on: utilizing advanced technology to elucidate its key functional targets and signaling pathways; Conduct systematic preclinical pharmacokinetic and safety evaluations; And through rational medicinal chemical methods for structural optimization, in order to obtain derivatives with stronger activity, higher safety, and better drug properties. The research process of Ranaconitine is a typical exploration of transforming the "poison" of traditional Chinese medicine into a modern "good medicine". Its success depends not only on scientific breakthroughs, but also on interdisciplinary integration and persistent efforts.
